A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined with the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors

Journal of Immunotherapy

Volumn 38, Issue 8, 2015, Pages 311-320

  Gérard, Catherine ^a   Baudson, Nathalie ^a   Ory, Thierry ^a   Segal, Lawrence ^a   Louahed, Jamila ^a  

^a GSK   (Belgium)

Author keywords

animal models; AS15 immunostimulant; cancer immunotherapy; PRAME tumor antigen; tumor protection

Indexed keywords

ANTINEOPLASTIC AGENT; AS 15; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR1 ANTIGEN; IMMUNOSTIMULATING AGENT; PHOSPHATE BUFFERED SALINE; PRAME ANTIGEN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG; ANTIBODY; IMMUNOLOGICAL ADJUVANT; PRAME PROTEIN, HUMAN; RECOMBINANT PROTEIN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SIZE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL EXAMINATION; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNE RESPONSE; MACACA FASCICULARIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; ANIMAL; BLOOD; COMBINATION DRUG THERAPY; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; DRUG THERAPY, COMBINATION; FEMALE; IMMUNOTHERAPY; MACACA FASCICULARIS; MALE; MICE; MICE, TRANSGENIC; NEOPLASMS; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 84941948127     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000095     Document Type: Article

References (65)

1. Aldrich JF, Lowe DB, Shearer MH, et al. Vaccines and immunotherapeutics for the treatment of malignant disease. Clin Dev Immunol. 2010;2010:697158. doi:10.1155/2010/697158.
2. Bilusic M, Gulley JL. Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother. 2012;61:109-117.
3. Vergati M, Intrivici C, Huen NY, et al. Strategies for cancer vaccine development. J Biomed Biotechnol. 2010;2010:596432. doi:10.1155/2010/596432.
4. Palumbo MO, Kavan P, Miller WH Jr, et al. Systemic cancer therapy: Achievements and challenges that lie ahead. Front Pharmacol. 2013;4:57. doi:10.3389/fphar.2013.00057.
5. Charoentong P, Angelova M, Efremova M, et al. Bioinformatics for cancer immunology and immunotherapy. Cancer Immunol Immunother. 2012;61:1885-1903.
6. Finn OJ. Cancer immunology. N Engl J Med. 2008;358: 2704-2715.
7. Laheru DA, Pardoll DM, Jaffee EM. Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. Mol Cancer Ther. 2005;4:1645-1652.
8. Hammer GE, Kanaseki T, Shastri N. The final touches make perfect the peptide-MHC class I repertoire. Immunity. 2007; 26:397-406.
9. Buonaguro L, Petrizzo A, Tornesello ML, et al. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol. 2011;18:23-34.
10. Palena C, Schlom J. Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol. 2010;2010:380697. doi:10.1155/2010/380697.
11. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol. 2003;21:807-839.
12. Andersen MH, Junker N, Ellebaek E, et al. Therapeutic cancer vaccines in combination with conventional therapy. J Biomed Biotechnol. 2010;2010:237623. doi:10.1155/2010/237623.
13. Dimberu PM, Leonhardt RM. Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. Yale J Biol Med. 2011;84:371-380.
14. Postow M, Callahan MK, Wolchok JD. Beyond cancer vaccines: A reason for future optimism with immunomodulatory therapy. Cancer J. 2011;17:372-378.
15. Weir GM, Liwski RS, Mansour M. Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines. Cancers. 2011;3:3114-3142.
16. Chiang CL, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol. 2010;22:132-143.
17. Dubensky TW Jr, Reed SG. Adjuvants for cancer vaccines. Semin Immunol. 2010;22:155-161.
18. Kirkwood JM, Butterfield LH, Tarhini AA, et al. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62:309-335.
19. Tefit JN, Serra V. Outlining novel cellular adjuvant products for therapeutic vaccines against cancer. Expert Rev Vaccines. 2011;10:1207-1220.
20. Ikeda H, Lethe B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6:199-208.
21. Tajeddine N, Gala JL, Louis M, et al. Tumor-Associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res. 2005;65: 7348-7355.
22. Atanackovic D, Luetkens T, Kloth B, et al. Cancer-Testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol. 2011;86:918-922.
23. Ding K, Wang XM, Fu R, et al. PRAME gene expression in acute leukemia and its clinical significance. Cancer Biol Med. 2012;9:73-76.
24. Doolan P, Clynes M, Kennedy S, et al. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat. 2008;109:359-365.
25. Heighway J, Knapp T, Boyce L, et al. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene. 2002;21:7749-7763.
26. Szczepanski MJ, DeLeo AB, Luczak M, et al. PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions. Oral Oncol. 2013;49:144-151.
27. van Baren N, Chambost H, Ferrant A, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol. 1998;102:1376-1379.
28. Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A(∗)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med. 2001;193:73-88.
29. Costessi A, Mahrour N, Sharma V, et al. The human EKC/KEOPS complex is recruited to Cullin2 ubiquitin ligases by the human tumour antigen PRAME. PLoS One. 2012;7:e42822.
30. Costessi A, Mahrour N, Tijchon E, et al. The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters. EMBO J. 2011;30:3786-3798.
31. Quintarelli C, Dotti G, Hasan ST, et al. High-Avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 2011;117:3353-3362.
32. Griffioen M, Kessler JH, Borghi M, et al. Detection and functional analysis of CD8+ T cells specific for PRAME: A target for T-cell therapy. Clin Cancer Res. 2006;12:3130-3136.
33. Li L, Giannopoulos K, Reinhardt P, et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol. 2006;28:855-861.
34. Rezvani K, Yong AS, Tawab A, et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAMEspecific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood. 2009;113: 2245-2255.
35. Amir AL, van der Steen DM, van Loenen MM, et al. PRAMEspecific allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer. Clin Cancer Res. 2011;17:5615-5625.
36. The European Parliament and the Council of the European Union. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Official Journal of the European Union. 2010;L 276:33-79. Available at: http://eur-lex. europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033: 0079:en:PDF. Accessed February 21, 2014.
37. Organisation for Economic Co-operation and Development (OECD). OECD Principles on Good Laboratory Practice (as revised in 1997). 1998. Available at: http://search.oecd.org/officialdocuments/displaydocumentpdf/?doclanguage=en&cote= env/mc/chem(98)17. Accessed February 21, 2014.
38. The European Parliament and the Council of the European Union. Directive 2004/10/EC of the European Parliament and of the Council of 11 February 2004 on the harmonisation of laws, regulations and administrative provisions relating to the application of the principles of good laboratory practice and the verification of their applications for tests on chemical substances. Official Journal of the European Union. 2004;L 50:44-50. Available at: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32004L0010&from=EN. Accessed February 21, 2014.
39. Ministère de lEmploi et de la Solidarité . Arreté du 14 mars 2000 relatif aux bonnes pratiques de laboratoire. 2000. Available at: http://ansm.sante.fr/var/ansm-site/storage/original/application/dd4641e3edd1885e60f0337d4c385b5e.pdf. Accessed February 21, 2014.
40. The Council of the European Communities. Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes 1986. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX: 31986L0609:en:HTML. Accessed February 21, 2014.
41. Destexhe E, Grosdidier E, Baudson N, et al. Non-clinical safety evaluation of single and repeated intramuscular administrations of MAGE-A3 cancer immunotherapeutic in rabbits and Cynomolgus monkeys. J Appl Toxicol. 2015;35:717-728.
42. Wang M, Bronte V, Chen PW, et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-Associated antigen. J Immunol. 1995;154:4685-4692.
43. Aebig JA, Mullen GE, Dobrescu G, et al. Formulation of vaccines containing CpG oligonucleotides and alum. J Immunol Methods. 2007;323:139-146.
44. Weeratna RD, Makinen SR, McCluskie MJ, et al. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine. 2005;23:5263-5270.
45. Weigel BJ, Rodeberg DA, Krieg AM, et al. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res. 2003;9:3105-3114.
46. Garcon N, Silvano J, Kuper CF, et al. Non-clinical safety evaluation of repeated intramuscular administration of the AS15 immunostimulant combined with various antigens in rabbits and Cynomolgus monkeys. J Appl Toxicol. 2015. DOI 10.1002/jat.3167. [Epub ahead of print].
47. Fisher RA. Statistical Methods for Research Workers, 14th ed. New York, NY: Hafner Publishing Company; 1973.
48. Dean AM, Voss D. Design and Analysis of Experiments (Springer Texts in Statistics). New-York: Springer; 2000.
49. Atanackovic D, Altorki NK, Cao Y, et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-Term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A. 2008;105:1650-1655.
50. Atanackovic D, Altorki NK, Stockert E, et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol. 2004;172:3289-3296.
51. Chen J, Zhang L, Wen W, et al. Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice. PLoS One. 2012;7:e47219.
52. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol. 2010;667:111-123.
53. Daayana S, Elkord E, Winters U, et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer. 2010;102: 1129-1136.
54. Kruit WH, Suciu S, Dreno B, et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol. 2013;31:2413-2420.
55. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005;115:739-746.
56. Valmori D, Souleimanian NE, Tosello V, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A. 2007;104: 8947-8952.
57. van Ojik H, Kruit W, Portielje J, et al. Phase I/II study with CpG 7909 as adjuvant to vaccination with MAGE-3 protein in patients with MAGE-3 positive tumors (abstract). Ann Oncol. 2002;13(suppl 5):157-162.
58. Vantomme V, Dantinne C, Amrani N, et al. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother. 2004;27: 124-135.
59. Zhang L, Chen J, Song X, et al. Cancer/testis antigen HCA587-derived long peptide vaccine generates potent immunologic responses and antitumor effects in mouse model. Oncol Res. 2013;21:193-200.
60. Pajot A, Michel ML, Fazilleau N, et al. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-Transgenic H-2 class I-/class II-knockout mice. Eur J Immunol. 2004;34:3060-3069.
61. Gonzalez-Galarza FF, Christmas S, Middleton D, et al. Allele frequency net: A database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 2011;39:D913-D919.
62. Vansteenkiste J, Zielinski M, Linder A, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol. 2013;31:2396-2403.
63. Kilpinen S, Autio R, Ojala K, et al. Systematic bioinformatic analysis of expression levels of 17, 330 human genes across 9, 783 samples from 175 types of healthy and pathological tissues. Genome Biol. 2008;9:R139.
64. Pollack SM, Li Y, Blaisdell MJ, et al. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One. 2012;7:e32165.
65. Weber JS, Vogelzang NJ, Ernstoff MS, et al. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother. 2011;34:556-567.